11 Apr
  • By cure.duchenne
  • Cause in

Drisapersen, Etiplersen, GSK, Prosensa and Sarepta, a Positive Week for Duchenne

Thanks to GSK, Prosensa and Sarepta and, the landscape is changing for the patients and families that are suffering from Duchenne, a severe muscle disease that shortens the life expectancy and quality of life for approximately 300,000 boys and young men worldwide. Even though these potential treatments that are currently in the news have not […]

READ MORE
09 Apr
  • By cure.duchenne
  • Cause in

DRISAPERSEN TREATMENT FOR DUCHENNE MUSCULAR DYSTROPHY: RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL

It’s been almost 10 years since CureDuchenne funded a little know biotech company, Prosensa, in the Netherlands.  With only $10,000 in our bank account, we committed to fund a $1.3 Million project to develop antisense (exon skipping) for Duchenne.  A few years later, venture capital firms validated our investment with several million dollars to continue their research.  […]

READ MORE
08 Apr
  • By cure.duchenne
  • Cause in

Update from GSK on drisapersen (previously GSK2402968)

GSK will be announcing results from their Phase llb study this week.  We will keep you updated on the news as it comes in.  Here is the note from GSK: ———————————————————————————————————————————————- To keep you updated on the progress of the drisapersen (previously GSK2402968) clinical development program, as you have requested, I am writing to inform […]

READ MORE
05 Apr
  • By cure.duchenne
  • Cause in

Sarepta Therapeutics Announces Eteplirsen Demonstrates Sustained Benefit on Walking Test Through 74 Weeks in Phase IIb Study in Duchenne Muscular Dystrophy

Data to Be Presented at the Muscular Dystrophy Association Scientific Conference CAMBRIDGE, MA–(Marketwired – April 05, 2013) – Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today announced updated data from Study 202, a Phase IIb open-label extension study of eteplirsen in patients with Duchenne muscular dystrophy (DMD). Results at 74 weeks […]

READ MORE
21 Mar
  • By cure.duchenne
  • Cause in

SUMMIT OUTLINES CLINICAL DEVELOPMENT PLANS FOR UTROPHIN MODULATOR PROGRAMME FOR DUCHENNE MUSCULAR DYSTROPHY

• First patient clinical trials of SMT C1100 expected to start H2 2013 •Summit to showcase programme at international scientific conference Oxford, UK, 21 March 2013 – Summit (AIM: SUMM), a drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy (‘DMD’) and C. difficile infections, today outlines its future plans for the continued […]

READ MORE
04 Mar
  • By cure.duchenne
  • Cause in

Drisapersen/GSK Update

Dear Debra, Since my last email you may have seen a recent story that appeared on an investment tips website regarding a presentation on drisapersen made at the Duchenne Parent Project Onlus meeting on 24th February 2013 in Rome, Italy. We appreciate that the story may raise questions for you, so I wanted to write and […]

READ MORE
21 Feb
  • By cure.duchenne
  • Cause in

FDA Webinar on Accelerated Approval Summary

    CureDuchenne was honored to host a webinar today, in collaboration with PPMD and MDA to discuss accelerated approval for drugs for rare diseases.   Dr. Robert Temple, director of the Office of Medical Policy of FDA’s Center for Drug Evaluation and Research presented detailed information on the different options available to speed the approval of […]

READ MORE
29 Jan
  • By cure.duchenne
  • Cause in

Prosensa Achieves Orphan Drug Status on its Entire

  Leiden, The Netherlands – 29 January 2013 – Prosensa, the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, announced it has achieved orphan drug designation in the EU and the US for all of its compounds for the treatment of Duchenne muscular dystrophy (DMD). The European Medicines Agency […]

READ MORE
10 Jan
  • By cure.duchenne
  • Cause in

GSK Exon 51 Trial Update

GSK has sent out this update on their Duchenne trial.  The last patient has been recruited within the drisapersen US Phase II clinical study [www.clinicaltrials.gov NCT01462292]. This exploratory study aims to assess the safety, efficacy and pharmacokinetics of two doses of drisapersen in the treatment of ambulant boys with DMD who have a dystrophin gene […]

READ MORE
28 Dec
  • By cure.duchenne
  • Cause in

Cure Duchenne Supports Duchenne Duplication Mutation Research with Dr. Kevin Flanigan

  Exon duplication mutations have been an area of great interest to CureDuchenne, and last year, CureDuchenne funded research specifically directed toward these mutations in Duchenne.  Dr. Kevin Flanigan at Nationwide Children’s Hospital has successfully completed the first phase of his research (please see below). CureDuchenne will continue to fund his work in 2013. The three […]

READ MORE